Group 1 - The core point of the announcement is the resolution of the first extraordinary general meeting of shareholders of Hangzhou Botao Biotechnology Co., Ltd. held on January 26, 2026, with no rejected proposals [1][2] - The meeting was convened in accordance with the Company Law, Securities Law, and the company's articles of association, utilizing a combination of on-site and online voting methods [2][5] - The meeting was attended by 6 out of 7 current directors, with one independent director participating via communication, and the company’s vice president and board secretary also present [3] Group 2 - Two main proposals were reviewed: the revision of the company's articles of association and the anticipated daily related party transactions for 2026, both of which were approved [4][5] - The first proposal required a special resolution, passing with more than two-thirds of the voting rights held by attending shareholders, while the second proposal was a general resolution, passing with more than half of the voting rights [5] - The meeting was witnessed by Zhejiang Tian Ce Law Firm, confirming that the convening and proceedings of the meeting complied with legal and regulatory requirements [5]

2026 年第一次临时股东会的 法律意见书 浙江天册律师事务所 关 于 杭州博拓生物科技股份有限公司 天册律师事务所 杭州市杭大路 1 号黄龙世纪广场 A 座 11 楼 电话：+ 86 571 8790 1110 传真：+ 86 571 8790 1500 www.tclawfirm.com 法律意见书 浙江天册律师事务所 关于杭州博拓生物科技股份有限公司 2026 年第一次临时股东会的 法律意见书 编号：TCYJS2026H0118 号 法律意见书 （1）《关于修订<公司章程>及修订、新增部分制度的议案》； 致：杭州博拓生物科技股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和 国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下简称"《股 东会规则》"）等法律、法规和规范性文件及《杭州博拓生物科技股份有限公司章 程》（以下简称"《公司章程》"）的有关规定，浙江天册律师事务所（特殊普通 合伙）（以下简称"本所"）接受杭州博拓生物科技股份有限公司（以下简称"博 拓生物"或"公司"）的委托，指派律师参加博拓生物 2026 年第一次临时股东会， 并出具本法律意见书。 ...

证券代码：688767 证券简称：博拓生物 公告编号：2026-007 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2026 年 1 月 26 日 （二） 股东会召开的地点：杭州市余杭区仓前街道途义路 27 号 A 幢 110 室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 57 | | --- | --- | | 普通股股东人数 | 57 | | 2、出席会议的股东所持有的表决权数量 | 61,718,619 | | 普通股股东所持有表决权数量 | 61,718,619 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 41.3294 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 41.3294 | （四） 表决方式是否符合《公司法》及公司章程的规定，股东会主持情况等。 ...

Core Viewpoint - The company, Hangzhou Botao Biotechnology Co., Ltd., anticipates a decline in revenue and net profit for 2025 due to the impact of U.S. tariff policies and cyclical fluctuations in the infectious disease market, but expects steady growth in 2026 with new product registrations and strategic investments in the brain-computer interface (BCI) industry [1][2]. Financial Performance - The company forecasts a significant drop in net profit for 2025, primarily due to revenue declines from U.S. tariffs and cyclical market demand fluctuations, alongside increased R&D and stock incentive costs [2]. - Despite short-term performance pressures, the company is optimistic about 2026 being a turning point for revenue and profit growth, supported by new product registrations and stable tariff conditions [2]. Product Development and Innovation - The company is accelerating the development of its microfluidic technology platform, focusing on cardiac markers, thyroid function, and nutrition-related projects, with breakthroughs in multi-project detection on a single chip [2]. - The company has received FDA510(k) approval for fentanyl testing and is progressing with various microfluidic product registrations in China, the EU, and Southeast Asia [2]. Strategic Expansion in Brain-Computer Interface - The company is actively investing in the BCI sector, aiming to establish it as a second core business through direct investments and partnerships [3]. - A strategic investment in Hangzhou Qingshi Yongjun has been made, focusing on invasive BCI treatments for treatment-resistant depression, with clinical trials already underway [3][4]. - The company has also invested in Hangzhou Haoshi Tianhui, which focuses on non-invasive BCI technologies for mental health assessments, with plans for product promotion and sales in 2026 [5][6]. Industry Ecosystem Development - The company plans to establish a specialized industry fund for the BCI sector, with a total scale of 200 million yuan, to enhance collaboration and development within the medical device ecosystem [6]. - The company is committed to building a synergistic medical device ecosystem in the BCI industry, recognizing it as a long-term investment opportunity in the healthcare sector [6].

- The report discusses a **quantitative timing model based on volume signals**, which indicates a "bullish" view for all major indices except the ChiNext Index as of January 23, 2026[30][31][33] - A **momentum sentiment indicator** is introduced, calculated as the proportion of stocks in the CSI 300 Index with positive returns over the past N days. The indicator is smoothed using two moving averages (N1=50, N2=35). When the short-term average exceeds the long-term average, it signals a bullish market sentiment[32][34][36] - The **moving average sentiment indicator** is based on the eight moving averages (8, 13, 21, 34, 55, 89, 144, 233). The indicator assigns values of -1, 0, or 1 based on the position of the current price relative to these moving averages. A value greater than 5 indicates a bullish signal for the CSI 300 Index[40][44] - The **cross-sectional volatility factor** is analyzed, showing that the CSI 300 Index's cross-sectional volatility increased week-over-week, indicating an improved short-term alpha environment. Conversely, the cross-sectional volatility for the CSI 500 and CSI 1000 indices decreased, suggesting a deteriorated alpha environment[45][46] - The **time-series volatility factor** is also evaluated, revealing that the time-series volatility for the CSI 300, CSI 500, and CSI 1000 indices decreased week-over-week, indicating a worsening alpha environment. Over the past quarter, the CSI 300 Index's volatility was in the lower range of the past six months, while the CSI 500 and CSI 1000 indices were in the middle range[46][49]

Core Insights - The main viewpoint of the article highlights the limitations of traditional mental health diagnostic methods and introduces a non-invasive brain-computer interface technology as a more efficient and objective solution for diagnosing conditions like depression and anxiety [1] Group 1: Current Diagnostic Methods - Current mainstream methods for diagnosing mental health issues rely on a combination of "scale assessment + comprehensive judgment by doctors," which is time-consuming and difficult to quantify [1] - In non-hospital settings, such as community screenings or corporate health management, the lack of professional psychological resources can lead to subjective biases in results [1] Group 2: Innovative Solutions - The non-invasive brain-computer interface technology offers a solution by utilizing real-time EEG signal collection and AI analysis for efficient and objective assessments [1] - The core competitive advantage of Haoshi Tianhui lies in its fully self-developed non-invasive brain-computer interface technology system, which includes high-precision AI algorithms that decode EEG signals into quantifiable emotional indicators [1] Group 3: Product Features and Efficacy - The developed system can conduct tests for depression and anxiety in as little as 90 seconds per session, achieving an accuracy rate of over 90% [1] - The system has received medical device registration certification and integrates a software platform that generates customized therapeutic music based on real-time EEG data, creating a complete "assessment-intervention-feedback" loop [1] Group 4: Market Potential and Expansion - The solution significantly reduces subjective bias and enhances screening efficiency, making it applicable in various settings such as hospitals, education, and justice [1] - Recent policy support in China for mental health diagnosis, including the incorporation of AI+EEG diagnostics into national medical guidelines, creates favorable commercialization conditions [1] - Haoshi Tianhui has initiated collaborations with medical institutions and distributors in regions like Yunnan, Guizhou, Sichuan, Jiangxi, Guangdong, Hebei, and Jiangsu-Zhejiang-Shanghai to accelerate product scaling [1] - Future plans include expanding into consumer applications through the sale of devices and consumables, as well as a system service model to achieve sustainable revenue growth [1]

Core Viewpoint - The brain-computer interface (BCI) industry is identified as a long-term investment opportunity in the healthcare sector, with significant strategic importance for the company in the medical device field [1] Summary by Relevant Sections Industry Outlook - The implementation opinions jointly issued by seven departments, including the Ministry of Industry and Information Technology, aim to establish an advanced technology, industry, and standard system for the BCI industry by 2027, and to cultivate 2 to 3 globally influential leading enterprises by 2030 [1] Company Strategy - The company has been researching and exploring the BCI direction since 2023 and strategically invested in Hangzhou Qingshi Yongjun in 2025, successfully entering the invasive BCI treatment field for severe treatment-resistant depression [1] - The recent investment in Haoshi Tianhui further enhances the company's detection and treatment layout for depression and anxiety disorders within the BCI field [1] Future Plans - The company plans to continue its strategic layout in the BCI field by participating deeply through its investment platform, using its own funds for equity participation or acquisitions to accelerate the product industrialization and commercialization processes of invested enterprises [1] - Additionally, the company intends to establish a BCI industry fund, leveraging the strengths and resources of professional investment institutions to expedite its industrial chain layout in the BCI and neuroscience fields [1]

Core Viewpoint - Botao Bio announced the appointment of Dai Qi as the new sponsor representative for its ongoing supervision during the IPO process on the Sci-Tech Innovation Board, following a personnel change due to personal reasons of the previous representative [2] Group 1 - Botao Bio's IPO process is being supervised by Guotai Junan Securities, with the supervision period lasting until December 31, 2024 [2] - The company has not yet fully utilized the funds raised from the IPO, prompting continued oversight of the fund's storage and usage [2] - Dai Qi, the newly appointed sponsor representative, possesses substantial investment banking experience and is deemed capable of fulfilling the supervisory responsibilities [2]

Group 1 - The core point of the article is that Botao Bio has announced a significant decrease in its expected net profit for the year 2025, projecting a net profit of approximately 45 million yuan, which represents a year-on-year decrease of about 73.45% [1] - The company anticipates a reduction of around 124.5155 million yuan compared to the previous year's legally disclosed data [1]

Core Viewpoint - The company focuses on the research, development, production, and sales of POCT reagents and instruments, with a significant portion of its revenue derived from drug abuse testing and infectious disease testing, which together account for approximately 80% of total revenue [1] Group 1: Business Focus - The company's main products include drug abuse testing, infectious disease testing, reproductive health testing, tumor marker testing, and cardiac marker testing [1] - Approximately 75% of the company's revenue comes from overseas sales, indicating a strong international market presence [1] Group 2: Financial Outlook - The company anticipates a significant decline in operating revenue in 2025 due to multiple rounds of tariff policies from the U.S. government and cyclical fluctuations in the infectious disease testing market, particularly for respiratory and tropical diseases [1] - Increased R&D expenses and share-based payment costs are expected to put additional pressure on the company's performance [1] Group 3: Future Prospects - Despite the challenges, the company is confident in maintaining steady revenue growth in 2026, supported by the introduction of differentiated competitive products and the ongoing approval of product registration certificates [1] - Notable achievements include the FDA 510(k) approval for fentanyl testing (OTC) in October 2025 and the gradual approval of IVDR certificates, along with the registration of microfluidic fluorescent immuno POCT products in China, the EU, and Southeast Asia [1]